DAIC

MARCH 12, 2025

This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients. This innovative approach not only addresses that need but also improves patient outcomes, ensuring a better quality of life for those diagnosed with A-Fib.

Ablation 52

Ablation Innovation Quality of Life Atrial Fibrillation 52

DAIC

APRIL 9, 2024

Four heart rhythm organizations from around the globe developed the statement. It is also published in Heart Rhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS.

Atrial Fibrillation 105

Atrial Fibrillation Ablation Heart Rhythm Blood Clot 105

MIBHS

JANUARY 31, 2025

The Role of Wearable Technology in Heart Health Wearable tech is designed to monitor physiological data and provide actionable insights to users. For heart health, these devices use advanced sensors to track metrics like heart rate, blood oxygen levels, and even irregular heart rhythms.

Heart Rhythm 52

Heart Rhythm Technology AFIB Exercise 52

DAIC

DECEMBER 27, 2023

The robotic technology represented an entirely novel way to address heart rhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

Technology 105

Technology Heart Disease Heart Rhythm Arrhythmia 105

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

DAIC

JANUARY 19, 2024

milla1cf Fri, 01/19/2024 - 10:38 January 19, 2024 — Heart rhythm expert Sumeet Chugh, MD , associate director of the Smidt Heart Institute at Cedars-Sinai , is the recipient of this year’s American College of Cardiology ( ACC ) Distinguished Scientist Award-Clinical Domain. Photo by Cedars-Sinai.

Cardiac Arrest 105

Cardiac Arrest Heart Rhythm Electrophysiology Sudden Cardiac Death 105

DAIC

JULY 16, 2024

At the forefront of PowerPlugs is AFib Detection , a PowerPlug that discreetly monitors your heart rhythm every night to detect signs of Atrial Fibrillation (AFib). AFib is the most common type of irregular heart rhythm or arrhythmia. UltraSignal will help fuel more customization and innovation in health.

AFIB 105

AFIB Technology Heart Rhythm Arrhythmia 105

DAIC

MARCH 12, 2025

This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients. This innovative approach not only addresses that need but also improves patient outcomes, ensuring a better quality of life for those diagnosed with A-Fib.

Ablation 52

Ablation Innovation Quality of Life Atrial Fibrillation 52

DAIC

JANUARY 24, 2024

The Smidt Heart Institute recently received CAROL Act funding to study the connection between ventricular arrhythmias—abnormal heartbeats that start in the heart’s two lower chambers—and an elevated risk of sudden cardiac death in patients with mitral valve disease. Patients come to us from all over the U.S.

Bicuspid/Mitral 105

Bicuspid/Mitral Research Heart Valves Cardiac Arrest 105

HeartRhythm

MARCH 26, 2024

Wilkoff, MD, one of the most impactful and pioneering members of the Heart Rhythm Society (HRS). Dr Wilkoff was an innovator in the field of cardiac implantable electronic devices (CIEDs).

Heart Rhythm 45

Heart Rhythm Electrophysiology Innovation Technology 45

DAIC

FEBRUARY 2, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3

Ablation 105

Ablation Atrial Fibrillation AFIB Heart Rhythm 105

DAIC

MARCH 28, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., Food & Drug Administration ( FDA ).

Atrial Fibrillation 110

Atrial Fibrillation AFIB Ablation Pulmonary 110

DAIC

DECEMBER 22, 2023

David Newton , Clinical Cardiac Electrophysiologist at Memorial Health University Physicians Heart Care and Dr. Andrea Natale , Executive Medical Director at T exas Cardiac Arrhythmia Institute, St. David’s Medical Center. Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib.

Atrial Fibrillation 59

Atrial Fibrillation AFIB Ablation Arrhythmia 59

DAIC

MARCH 5, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). [ii]

Ablation 59

Ablation Atrial Fibrillation Atrial Flutter Pulmonary 59

Vector Remote

APRIL 14, 2023

History & Future of Cardiac Remote Patient Monitoring Healthcare reforms fueled by government legislation and recent technological innovations have propelled cardiac remote patient monitoring to the forefront in the early 2020s, but the history of cardiac remote patient monitoring dates to more than half a century ago.

Pacemaker 52

Pacemaker Technology COVID-19 Arrhythmia 52

Cardiomatics

AUGUST 4, 2022

Over a short time, it is able to detect 20 different arrhythmias. It can help shorten queues to cardiologists, extend prevention and treatment to a wider group of patients, offer precise and early detection of heart rhythm abnormalities, reduce bureaucracy , and increase time for doctor-patient contact.

Cardiovascular Disease 52

Cardiovascular Disease Technology COVID-19 Coronary Artery Disease 52

DAIC

APRIL 6, 2024

EDT, the ACC will present Sumeet Chugh, MD , associate director of the Smidt Heart Institute, with this year’s Distinguished Scientist Award-Clinical Domain. Gupta is one of 28 structural heart cardiologists and surgeons selected for CTR’s new Project REACH. EDT, and she will co-chair electrophysiology research presentations.

Research 105

Research Cardiac Arrest Electrophysiology Chest Pain 105

Cardiometabolic Health Congress

JANUARY 2, 2025

Significance: Landiolol offers a new, highly selective beta-1 blocker for managing abnormally fast heart rhythms, addressing an important need in cardiac health management. Heart rate reduction within 10 minutes : Landiolol: 40%-90%. Heart rate decrease criteria: >20% decrease, HR <100 bpm, or arrhythmia cessation.

Coronary Artery Disease 52

Coronary Artery Disease Stents Stent Innovation 52